FDA Brief

Warning letters Devices

FDA warning letter to

Diasol, Inc.

High riskIssued Jan 29Posted Mar 3Center for Devices and Radiological Health

Diasol sold unapproved citric acid hemodialysis disinfectants and had quality system violations, FDA says.

What happened

FDA inspected Diasol’s Phoenix, AZ facility from July 21 to August 19, 2025. FDA found the firm’s 20% and 50% citric acid solutions for cleaning, decalcifying, and heat-disinfecting hemodialysis machines lacked required premarket approval or IDE and were not 510(k)-notified. The inspection also found Quality System violations, including acceptance limits outside the chosen standard, missing dextrose results before release, and inadequate validation of drum cleaning, mixing, water systems, and microbial testing.

What FDA found

  1. The 20% and 50% citric acid solutions for cleaning, decalcifying, and heat-disinfecting hemodialysis machines were adulterated and misbranded because they lacked premarket approval or an IDE and were not 510(k)-notified.

    21 U.S.C. § 351(f)(1)(B); 21 U.S.C. § 352(o); 21 U.S.C. § 360(k)
  2. Final acceptance procedures did not ensure electrolyte levels met the selected standard, and some batches were released without required dextrose test results.

    21 CFR § 820.80(d)
  3. Cleaning of reusable drums and mixing and water-system processes were not adequately validated, including missing raw data, unresolved failed tests, and an unvalidated mixing setup.

    21 CFR § 820.75(a)
  4. Microbiological testing and water-system monitoring were not properly implemented or controlled, including non-sterile sampling, expired syringes, out-of-range incubator temperatures, and unmonitored water parameters.

    21 CFR § 820.70(a)
  5. Warehouse temperature and humidity were not adequately monitored or controlled for finished products and raw materials requiring dry or cool storage.

    21 CFR § 820.70(a)

What FDA wants

FDA tells Diasol to correct the unapproved-device status and Quality System violations, including updating DMRs and acceptance limits, stopping use of noncompliant electrolyte ranges, and providing evidence of the planned corrections and validations. No response deadline is stated in the provided letter text.

Who should pay attention

  • dialysis clinics and providers
  • companies buying or distributing Diasol products
  • quality teams at dialysis solution and device manufacturers

This is a summary. Read the original letter on fda.gov.

Diasol, Inc.'s FDA history

Recalls in the last 12 months

Dec 31, 2025 Class II Diasol, Inc
Device
Brand Name: Diasol Product Name: 100425-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters
Safety and efficacy of dialysis acid concentrate cannot be assured
Dec 31, 2025 Class II Diasol, Inc
Device
Brand Name: Diasol Product Name: 100225-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters
Safety and efficacy of dialysis acid concentrate cannot be assured
Dec 31, 2025 Class II Diasol, Inc
Device
Brand Name: Diasol Product Name: 100220-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters
Safety and efficacy of dialysis acid concentrate cannot be assured
Dec 31, 2025 Class II Diasol, Inc
Device
Brand Name: Diasol Product Name: 100325-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters
Safety and efficacy of dialysis acid concentrate cannot be assured
Dec 31, 2025 Class II Diasol, Inc
Device
Brand Name: Diasol Product Name: 100125-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters
Safety and efficacy of dialysis acid concentrate cannot be assured
Dec 31, 2025 Class II Diasol, Inc
Device
Brand Name: Diasol Product Name: 100230-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters
Safety and efficacy of dialysis acid concentrate cannot be assured

Full company page

Similar letters to other companies

  1. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  4. Tides Medical LLC

    FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

    High risk